Success Metrics

Clinical Success Rate
100.0%

Based on 11 completed trials

Completion Rate
100%(11/11)
Active Trials
0(0%)
Results Posted
64%(7 trials)

Phase Distribution

Ph phase_3
5
36%
Ph phase_4
6
43%
Ph phase_2
2
14%

Phase Distribution

0

Early Stage

2

Mid Stage

11

Late Stage

Phase Distribution13 total trials
Phase 2Efficacy & side effects
2(15.4%)
Phase 3Large-scale testing
5(38.5%)
Phase 4Post-market surveillance
6(46.2%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

91.7%

11 of 12 finished

Non-Completion Rate

8.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

14

all time

Status Distribution
Completed(11)
Terminated(1)
Other(2)

Detailed Status

Completed11
unknown2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
14
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 22 (15.4%)
Phase 35 (38.5%)
Phase 46 (46.2%)

Trials by Status

completed1179%
unknown214%
withdrawn17%

Recent Activity

0 active trials
Showing 5 of 14
completedphase_4

Efficacy and Safety of Apremilast in Psoriasis

NCT06032858
completedphase_4

Efficacy of Oral Apremilast in the Treatment of Alopecia Areata at the Tertiary Care Hospital, Karachi.

NCT05926882
completedphase_2

Evaluating Safety & Efficacy of Apremilast in the Treatment of Cutaneous Disease in Patients With Recalcitrant Dermatomyositis

NCT03529955
withdrawnphase_4

Apremilast and Moderate to Severe Chronic Hand Dermatitis

NCT03741933
completedphase_4

Apremilast for RAS

NCT03690544
View all 14 trials

Clinical Trials (14)

Showing 14 of 14 trials
NCT06032858Phase 4

Efficacy and Safety of Apremilast in Psoriasis

Completed
NCT05926882Phase 4

Efficacy of Oral Apremilast in the Treatment of Alopecia Areata at the Tertiary Care Hospital, Karachi.

Completed
NCT03529955Phase 2

Evaluating Safety & Efficacy of Apremilast in the Treatment of Cutaneous Disease in Patients With Recalcitrant Dermatomyositis

Completed
NCT03741933Phase 4

Apremilast and Moderate to Severe Chronic Hand Dermatitis

Withdrawn
NCT03690544Phase 4

Apremilast for RAS

Completed
NCT03168256Phase 3

CF101 Therapy in Patients With Moderate-to-severe Plaque Psoriasis

Completed
NCT01307423Phase 3

Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)

Completed
NCT04555707Phase 4

The Maintenance Effect of Enstilar Foam in Combination With Otezla

Unknown
NCT01172938Phase 3

Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis

Completed
NCT00773734Phase 2

Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study)

Completed
NCT01212757Phase 3

PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis

Completed
NCT01212770Phase 3

PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis

Completed
NCT03399708

Immune Metabolic Associations in Psoriatic Arthritis

Completed
NCT03553433Phase 4

Apremilast Treatment for Pruritus and Quality of Life in Scalp Psoriasis

Unknown

All 14 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
14